American Association for Cancer Research
10780432ccr152840-sup-158595_1_supp_3347818_829706.pdf (488.58 kB)

Supplementary Figures S6-S10 from The Genomic Landscape of Male Breast Cancers

Download (488.58 kB)
journal contribution
posted on 2023-03-31, 19:26 authored by Salvatore Piscuoglio, Charlotte K.Y. Ng, Melissa P. Murray, Elena Guerini-Rocco, Luciano G. Martelotto, Felipe C. Geyer, Francois-Clement Bidard, Samuel Berman, Nicola Fusco, Rita A. Sakr, Carey A. Eberle, Leticia De Mattos-Arruda, Gabriel S. Macedo, Muzaffar Akram, Timour Baslan, James B. Hicks, Tari A. King, Edi Brogi, Larry Norton, Britta Weigelt, Clifford A. Hudis, Jorge S. Reis-Filho

Supplementary Figure S6: Amplifications in ER-positive/HER2-negative male and female breast cancers. Supplementary Figure S7: Copy number alterations in ER-positive/HER2-negative male and non-lobular female breast cancers. Supplementary Figure S8: Copy number alterations in male and post-menopausal female breast cancers. Supplementary Figure S9: Copy number alterations in male and non-lobular female breast cancers. Supplementary Figure S10: Amplifications in male breast cancers and female breast cancers/ post-menopausal female breast cancers.


Susan G Komen






Purpose: Male breast cancer is rare, and its genomic landscape has yet to be fully characterized. Lacking studies in men, treatment of males with breast cancer is extrapolated from results in females with breast cancer. We sought to define whether male breast cancers harbor somatic genetic alterations in genes frequently altered in female breast cancers.Experimental Design: All male breast cancers were estrogen receptor–positive, and all but two were HER2-negative. Fifty-nine male breast cancers were subtyped by immunohistochemistry, and tumor–normal pairs were microdissected and subjected to massively parallel sequencing targeting all exons of 241 genes frequently mutated in female breast cancers or DNA-repair related. The repertoires of somatic mutations and copy number alterations of male breast cancers were compared with that of subtype-matched female breast cancers.Results: Twenty-nine percent and 71% of male breast cancers were immunohistochemically classified as luminal A–like or luminal B–like, respectively. Male breast cancers displayed a heterogeneous repertoire of somatic genetic alterations that to some extent recapitulated that of estrogen receptor (ER)-positive/HER2-negative female breast cancers, including recurrent mutations affecting PIK3CA (20%) and GATA3 (15%). ER-positive/HER2-negative male breast cancers, however, less frequently harbored 16q losses, and PIK3CA and TP53 mutations than ER-positive/HER2-negative female breast cancers. In addition, male breast cancers were found to be significantly enriched for mutations affecting DNA repair–related genes.Conclusions: Male breast cancers less frequently harbor somatic genetic alterations typical of ER-positive/HER2-negative female breast cancers, such as PIK3CA and TP53 mutations and losses of 16q, suggesting that at least a subset of male breast cancers are driven by a distinct repertoire of somatic changes. Given the genomic differences, caution may be needed in the application of biologic and therapeutic findings from studies of female breast cancers to male breast cancers. Clin Cancer Res; 22(16); 4045–56. ©2016 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager